Venus Pharma GmbH (VPG) is a German pharmaceutical company and wholly-owned subsidiary of Venus Remedies Limited (India). Established in 2006 in Werne, Germany, VPG operates as a pharmaceutical hub providing licensing (EU CTD dossiers), contract manufacturing via partner facilities, packaging, warehousing, batch release, product testing, and distribution services. They hold 138+ marketing authorizations across 20 countries. Key products include anti-infectives (Meropenem flagship with 50% German market share, Ceftriaxone) and anti-cancer products (Gemcitabine with 33% UK market share). They achieved EU-GMP certification and WHO Prequalification for Meropenem. While they provide contract manufacturing services, the actual manufacturing appears to be performed at Venus Remedies Limited facilities in India rather than at VPG's own manufacturing plants. VPG functions primarily as a European regulatory, licensing, packaging, and distribution hub.
pharmaceutical licensing and dossier management, EU CTD preparation, contract packaging and warehousing, batch release, anti-infective/anti-cancer product distribution, Middle East and European market access
1 site worldwide
No reviews available yet.
No documents available.